Novus Acquisition & Development Corp. (OTC: NDEV), operating through its subsidiary WCIG Insurance Services, Inc. as Novus Cannabis MedPlan, released its interim financial results for the nine-month period ending September 30, 2026, reporting stable operational margins, disciplined capital management, and continued expansion of its health insurance and benefits administrative platform, according to a press release distributed by NEWMEDIAWIRE.
The company reported a 7.78% year-over-year increase in gross revenue, a 2.34% year-to-date expansion in total assets, and a 2.26% year-to-date increase in stockholders’ equity. Novus maintained a debt-to-equity ratio of 9.74% and held 0% convertible debt among its total liabilities. Corporate governance mandates remain strictly enforced, with 0% insider share liquidation over the trailing 36-month period and a 100% active Vendor Share Leak-Out Provision to mitigate market dilution.
Operating strictly as a health plan carrier and benefits administrator, Novus derives all revenues and profits from member plan fees and insurance policy premiums rather than the direct sale of controlled substances. This non-plant-touching model provides 100% operational segregation between its prescription drug plan and cannabis-adjacent distribution platform, insulating the company from federal cannabis scheduling delays and the heavy tax burdens of Internal Revenue Code Section 280E. The structure enables greater cost efficiency for policyholders, with a net 25% to 30% reduction in gross out-of-pocket expenditure at the point of sale, achieved through a 35% to 40% direct product discount and pre-tax funding via Health Savings Accounts (HSA) or Flexible Spending Accounts (FSA).
As medical marijuana emerges as a primary alternative healthcare focus for an estimated 65 million Americans, Novus is scaling its provider network to accommodate the demographic shift. The company has onboarded a new commercial provider, Upscale (www.shopupscalecbd.com), which delivers institutional-grade, broad-spectrum, THC-free formulations manufactured in an NSF GMP-compliant facility in Phoenix, Arizona. Upscale’s portfolio is underpinned by the rigorous NSF Certified for Sport designation, a credential that supports compliance frameworks and facilitates strategic alignment within high-performance and regulated athletic environments, helping NDEV expand its corporate distribution channels while maintaining disciplined risk management protocols.
For capital markets, NDEV’s intrinsic value is driven by its proprietary dual-platform infrastructure and non-plant-touching business model. By transitioning alternative medicine from the retail shelf to the structured benefits ledger, NDEV continues to build a resilient, non-cyclical market position. Comprehensive financial statements, Management Discussion and Analysis (MD&A), and Q3 2026 highlights are available through the company’s Investor Relations portal.
Investors can review the company’s financial filings at Click Here and access current stock quotes at Click Here.
